Trebananib (AMG 386) is an angiopoietin (Ang) 1 and 2 neutralizing peptibody that targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.
Accrual was stopped when the maximum sample size was reached. Predicted probabilities of success in a phase II trial was highest in the HR- signature, at 78.4%, short of the 85% threshold for graduation. There was some evidence of improved efficacy in HR-, MP+, HR-/HER2- and HER-/HER2+ tumors, with increased rates of pCR in the experimental arm, but not reaching statistical significance.